Ohio legislators have introduced bipartisan Senate and House bills aimed at curbing excessive fees charged by insurers and Pharmacy Benefit Managers to pharmacies and providers participating in the 340B Drug Pricing Program. The 340B Program,... Read More
Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Section 340B In-House and Contract Pharmacies

As another independent pharmacy closed its doors last week in Connecticut, the owner of the pharmacy identified that the rising costs of operations and direct and indirect remuneration (DIR) fees along with the decreasing reimbursement rates each... Read More
Defending Pharmacies in PBM Audits | DIR Fees | Fertility Pharmacies | Life Sciences | Pharmacy Law | Specialty Pharmacies

Download the webinar slides. The specialty pharmacy industry has dramatically changed over the past few years and is now one of the fastest growing sources of revenue in the prescription drug marketplace. As a result, payers and PBMs... Read More
Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Private Equity Investing in Specialty Pharmacy & Pharmaceutical Companies

The impact of Direct and Indirect Remuneration ("DIR") fees on the specialty pharmacy industry cannot be overstated and has been widely reported in White Papers and industry news reports. However, the impact of DIR fees on the 340B sector is only... Read More
Blogs & Articles | Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Section 340B In-House and Contract Pharmacies

A White Paper by Frier Levitt examines the ongoing practice by Pharmacy Benefit Managers (PBMs) to increase corporate profits through murky "Direct and Indirect Remuneration" fees—commonly known as "DIR Fees"—charged to community oncology... Read More
Blogs & Articles | Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Physician Dispensing